Insider Selling: Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells 6,613 Shares

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) EVP Jason Daly sold 6,613 shares of Amneal Pharmaceuticals stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $17.70, for a total transaction of $117,050.10. Following the transaction, the executive vice president owned 245,171 shares in the company, valued at $4,339,526.70. The trade was a 2.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Amneal Pharmaceuticals Stock Down 2.2%

Amneal Pharmaceuticals stock traded down $0.39 during trading on Thursday, reaching $17.27. 2,244,096 shares of the company’s stock were exchanged, compared to its average volume of 2,168,140. Amneal Pharmaceuticals, Inc. has a 52-week low of $9.15 and a 52-week high of $19.26. The firm has a market cap of $5.51 billion, a price-to-earnings ratio of 35.24 and a beta of 1.27. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20. The company’s 50-day moving average is $17.08 and its two-hundred day moving average is $14.54.

Analysts Set New Price Targets

AMRX has been the subject of a number of recent research reports. The Goldman Sachs Group reiterated a “buy” rating and issued a $21.00 target price on shares of Amneal Pharmaceuticals in a research note on Friday, July 31st. Zacks Research raised Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 7th. UBS Group upped their price target on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Weiss Ratings raised shares of Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, July 29th. Finally, Wall Street Zen upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, July 12th. One research analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $17.67.

Institutional Trading of Amneal Pharmaceuticals

Several large investors have recently modified their holdings of AMRX. Intech Investment Management LLC raised its stake in Amneal Pharmaceuticals by 1.2% during the fourth quarter. Intech Investment Management LLC now owns 97,573 shares of the company’s stock valued at $1,229,000 after buying an additional 1,159 shares in the last quarter. Hsbc Holdings PLC grew its position in shares of Amneal Pharmaceuticals by 1.6% in the 4th quarter. Hsbc Holdings PLC now owns 101,945 shares of the company’s stock worth $1,297,000 after acquiring an additional 1,569 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Amneal Pharmaceuticals by 2.4% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 68,137 shares of the company’s stock valued at $859,000 after acquiring an additional 1,582 shares during the last quarter. Comerica Bank increased its holdings in shares of Amneal Pharmaceuticals by 56.1% in the 4th quarter. Comerica Bank now owns 4,690 shares of the company’s stock valued at $59,000 after acquiring an additional 1,685 shares during the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of Amneal Pharmaceuticals during the 4th quarter valued at approximately $26,000. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.